Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating UniQure N.V. (NASDAQ: QURE) for potential securities law violations.
INVESTOR ALERT: Investigation of uniQure N.V. (QURE) Announced by Holzer & Holzer, LLC
03:36pm, Monday, 03'rd Nov 2025
INVESTOR ALERT: Investigation of uniQure N.V. (QURE) Announced by Holzer & Holzer, LLC ATLANTA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether uniQure N.V.
UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data
01:04pm, Monday, 03'rd Nov 2025
The U.S. Food and Drug Administration (FDA) provided feedback to uniQure N.V. (NASDAQ:QURE) regarding its investigational gene therapy for Huntington's disease, causing the stock to decline on Monday.
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm
12:30pm, Monday, 03'rd Nov 2025
LOS ANGELES--(BUSINESS WIRE)---- $QURE--QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm.
Uniqure stock plunges after FDA rejects company's clinical data for Huntington's therapy
10:56am, Monday, 03'rd Nov 2025
Uniqure NV (NASDAQ: QURE) shares plummeted more than 58% in early trading on Monday after the gene therapy company revealed that it was told by the US Food and Drug Administration (FDA) the cl
uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE
10:01am, Monday, 03'rd Nov 2025
LOS ANGELES--(BUSINESS WIRE)--uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE.
UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why.
08:11am, Monday, 03'rd Nov 2025
The company believes the Food and Drug Administration may deal a setback to one of its investigational therapies.
FDA says clinical data for UniQure's Huntington's disease therapy not adequate
07:18am, Monday, 03'rd Nov 2025
UniQure , said on Monday its experimental gene therapy for Huntington's disease does not have adequate clinical data to support its marketing application, according to the U.S. Food and Drug Administr
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
07:05am, Monday, 03'rd Nov 2025
LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
uniQure: 3-Year Huntington's Data Move AMT-130 From 'Promising' To 'Probable' (Rating Upgrade)
01:55pm, Tuesday, 28'th Oct 2025
uniQure (QURE) is upgraded to Buy following strong 36-month high-dose AMT-130 data for Huntington's disease, showing significant slowing of disease progression. QURE's AMT-130 demonstrated robust clin
uniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:08am, Tuesday, 28'th Oct 2025
uniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Breakout Momentum Plays You Need to Know About
08:17am, Thursday, 23'rd Oct 2025
Momentum investors rely on a combination of astute analysis and timing to maximize gains. While this approach can carry a fair degree of risk, the allure of identifying a fast-growing stock and joinin
KLP Kapitalforvaltning AS Invests $117,000 in uniQure N.V. $QURE
03:02am, Wednesday, 22'nd Oct 2025
KLP Kapitalforvaltning AS purchased a new position in shares of uniQure N.V. (NASDAQ: QURE) in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional
uniQure: Further Upside Likely As The Opportunity Becomes Better Understood
03:33pm, Wednesday, 08'th Oct 2025
uniQure surged over 300% following strong 3-year data from its Huntington's trial, yet remains undervalued due to skepticism over trial size and the use of external controls. AMT-130's apparent effica
QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop
04:15pm, Friday, 03'rd Oct 2025
In one of the most incredible single-day moves this year, biotechnology stock uniQure NASDAQ: QURE surged by 284% on Sept. 24. This came as the firm released fantastic clinical results for its develop
